

## Medtronic Wins Expanded Indication for SelectSecure(TM) MRI SureScan(TM) Pacing Lead for His Bundle Site Stimulation

GLOBE NEWSWIRE via COMTEX) --DUBLIN - July 12, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) labeling expansion for the Medtronic SelectSecure(TM) MRI SureScan(TM) Model 3830 cardiac pacing lead to include stimulation of the bundle of His. It is the only pacing lead on the market approved for His-bundle pacing (HBP).

The steroid-eluting, bipolar SelectSecure SureScan MRI model 3830 lead (lengths of 59, 69 and 74 cm) is attached to a single or dual chamber pacemaker, and approved for pacing and sensing in the atrium, right ventricle, or at the bundle of His as an alternative to right ventricular pacing. Lead placement at or near the bundle of His can be facilitated by the Medtronic C315HIS delivery catheter. Permanent His bundle pacing is a physiologic alternative to right ventricular pacing, harnessing the heart's native His-Purkinje system.

"There is growing interest among some physicians in His-bundle pacing as an alternative to right ventricular pacing, and we are pleased to offer the SelectSecure MRI lead for those who would like the option of this pacing approach for appropriate patients," said Rob Kowal, M.D., Ph.D., vice president and chief medical officer of the Cardiac Rhythm and Heart Failure division, which is part of the Cardiac and Vascular Group at Medtronic.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. Medtronic strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

### About Medtronic

Medtronic plc ([www.medtronic.com](http://www.medtronic.com)), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

### Contacts:

Tracy McNulty  
Public Relations  
+1-763-526-2492

Ryan Weispfenning  
Investor Relations  
+1-763-505-4626

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions

clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medtronic plc via Globenewswire

---

<https://news.medtronic.com/2018-07-12-Medtronic-Wins-Expanded-Indication-for-SelectSecure-TM-MRI-SureScan-TM-Pacing-Lead-for-His-Bundle-Site-Stimulation>